Prev: Effect of baclofen on esophagogastric motility and gastroesophageal reflux
Next: Watson fundoplication in children
From: trigonometry1972 on 13 Sep 2007 07:47
urr Gastroenterol Rep. 2004 Jun;6(3):213-9.

Gastroesophageal reflux disease and baclofen: is there a light at the
end of the tunnel?

Wise J, Conklin JL.

Department of Internal Medicine, Cedars-Sinai Medical Center, 8635
West Third Street, Suite 770W, Los Angeles, CA 90048, USA.

Transient lower esophageal sphincter relaxations (TLESRs) are rapid
and prolonged relaxations of the lower esophageal sphincter (LES) that
are not associated with swallowing. They are the mechanism by which
most gastroesophageal reflux episodes occur in normal people and in
patients with esophagitis. Transient LES relaxations appear to be
mediated by a vagovagal reflex initiated by gastric distention.
Baclofen is a g-aminobutyric acid (GABA) derivative that inhibits the
production of TLESRs by acting as a GABA(B) receptor agonist at one or
more loci along the vagovagal reflex arc. Animal and human studies
suggest that baclofen decreases the number of reflux events and amount
of esophageal acid exposure. Baclofen or another GABA(B) receptor
agonist may be clinically useful in treatment of gastroesophageal
reflux disease.

PMID: 15128488

 | 
Pages: 1
Prev: Effect of baclofen on esophagogastric motility and gastroesophageal reflux
Next: Watson fundoplication in children